®
  • Contact
  • Albumin
  • Products
    • Recombumin®
    • Sample page
  • Albumin Applications
    • COVID-19 Knowledge Hub
    • Cell therapy processing
    • Vaccine stabilization
    • Protein & Peptide formulation
    • Medical device coating
    • Veltis Technology
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

News & Events

World leading manufacturer of recombinant human albumin

Albumedix Media News & Events Commanders & Chiefs

Commanders & Chiefs

05 May 2020

"The role of chief technology officer has become more encompassing as companies adopt new software and technology-based solutions to solve some of their biggest challenges and create opportunities for new rewards."

Recently Albumedix' Chief Technology Officer, Phil Morton, contributed his thoughts on industry trends and the impact of evolving technology in a PharmaVoice feature focusing on ´Commanders & Chiefs.´

When reflecting on the biggest trends he's tracking in his role as Chief Technology Officer currently, Morton noted that within gene therapy, the move to better analytics is crucial to get a real understanding of the stability and efficacy of the viral vectors. While for cell therapies, extensions of cell stability and improvements in raw material consistency to reduce product variability are critical.

Follow the link below to access the full article and see how Mortons' opinions compare to other industry experts. 

Read the article on the PharmaVoice website here

 

CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. We partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with ~100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018

FOLLOW US

  • Albumin
  • Products
    • Recombumin®
    • Sample page
  • Albumin Applications
    • COVID-19 Knowledge Hub
    • Cell therapy processing
    • Vaccine stabilization
    • Protein & Peptide formulation
    • Medical device coating
    • Veltis Technology
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

We use cookies on our website to improve the website and your experience.

Read more